NEW ORLEANS, May 21, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Ca ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to misleading statements about the company's growth potential and subsequent stock price decline [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 8, 2024, to May 8, 2025 [3]. - Allegations include that Iovance provided overly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. - The company announced reduced revenue guidance for fiscal year 2024 due to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [3]. Stock Price Impact - Following the announcement of reduced guidance, Iovance's stock price fell from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, representing a decline of approximately 44.795% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated stock prices [5].

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025. SO WHAT: If you purchased Iovance securities during the Cla ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts clai ...

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet market demand for its cancer treatments [1][2]. Company Overview - Iovance Biotherapeutics is a biotechnology firm that specializes in cancer treatments [1]. - The lawsuit claims that the company and its executives made overly positive statements while concealing material adverse facts about its operational readiness [2][5]. Legal Proceedings - The class action lawsuit is titled Farberov v. Iovance Biotherapeutics, Inc., et al., and covers the period from May 9, 2024, to May 8, 2025 [1][2]. - The lead plaintiff deadline for the lawsuit is set for July 14, 2025 [2]. Financial Impact - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. - The company attributed its lower revenue guidance to a significant reduction in manufacturing capacity and lower-than-expected sales of its existing therapy, Proleukin [4]. Allegations of Misleading Information - The lawsuit argues that the disclosures made by Iovance revealed previously concealed issues that negatively impacted the company's growth prospects [5]. - Investors contend that earlier positive statements misrepresented Iovance's operational readiness and commercialization efforts [5].

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

On this news, the price of Iovance's shares fell 44.8%, from $1.42 per share to close at $1.75 per share on May 9, 2025, on unusually heavy trading volume. NEW YORK and NEW ORLEANS, May 20, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutic ...

Core Viewpoint - Iovance Biotherapeutics has seen a significant decline in its stock price, dropping nearly 78% since the beginning of 2025, despite having long-term growth potential [1] Financial Performance - Iovance's recent financial performance has raised concerns, with the company reporting a loss of $116 million for the first quarter of 2025 [6] - The company generated $49 million in sales for the first quarter, a substantial increase from less than $1 million in the same period last year, attributed to the launch of Amtagvi, a cellular therapy for melanoma [4] - However, Iovance has reduced its revenue guidance for 2025 to between $250 million and $300 million, down from a previous estimate of $450 million to $475 million [5] Cash Flow and Financial Stability - The company utilized nearly $104 million in cash from operating activities in the first three months of the year, indicating a concerning cash burn rate [9] - As of the end of the first quarter, Iovance had approximately $360 million in cash and short-term investments, which may not be sufficient to cover ongoing operational needs [9] - Frequent stock offerings may be necessary to sustain the business unless the company demonstrates strong sales growth [10] Market Sentiment and Future Outlook - Despite management's optimism about Amtagvi's potential to generate over $2 billion globally, investor sentiment appears to be cautious due to the slow rollout of the therapy [8] - The company is considered a risky investment, particularly for risk-averse investors, as it is still in the early stages of growth and may experience volatility [11]

NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/iovance-biotherapeutics-in ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].